NCT05662319Active, not recruitingPhase 3
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
A Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged ≥ 12 Years With Severe Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX who have switched from their prior standard of care treatment. The total study duration will be up to approximately 50 months (200 weeks, 1 study month is equivalent to 4 weeks) and will include: * A screening period up to approximately 60 days, * A standard of care (SOC) period of approximately 6 study months (24 weeks), * A fitusiran treatment period of approximately 36 study months (144 weeks), * An antithrombin (AT) follow-up period of approximately 6 study months (24 weeks) but may be shorter or longer depending on individual participants AT recovery. The frequency for telephone visits will be approximately every 2 weeks. For site visits the frequency will be approximately every 8 weeks during the SOC period and approximately every 4 weeks during the fitusiran treatment period. If applicable and if allowed by local regulation, home and/or remote visits may be conducted during the study
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 91 (actual)
- First submitted
- 14 Dec 2022
- Start date
- 1 Feb 2023
- Primary completion date
- 25 Mar 2027
- Lead sponsor
- Sanofi
- Diseases
- Haemophilia
- NCT number
- NCT05662319
- EU CT number
- 2022-500221-33-01
- EudraCT number
- 2022-500221-33
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 91
- From 1 Feb 2023 to the primary completion date, 25 Mar 2027
- 54 sites in 17 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current participation in immune tolerance induction therapy (ITI)
- Prior gene therapy
- Current or prior participation in a fitusiran trial
- Current or prior participation in a gene therapy trial
- Received an investigational drug or device within 30 days prior to the screening visit or within 5 half-lives of the investigational drug (or device) prior to the screening visit, whichever is longer
Other illness
- Known co-existing bleeding disorders other than congenital hemophilia A or B
- History of arterial or venous thromboembolism, not associated with an indwelling venous access
- History of intolerance to SC injection(s).
- Presence of clinically significant liver disease AT activity \<60% at Screening
- Co-existing thrombophilic disorder
- Hepatitis C virus antibody positive, except participants who have negative Hepatitis C viral load and no evidence of cirrhosis
- Presence of acute hepatitis, ie, hepatitis A, hepatitis E.
- Presence of acute or chronic hepatitis B infection
Lab values
- Known to be HIV positive with CD4 count \<200 cells/μL.
Other
- Reduced renal function The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Who the study is looking for
- Diagnosis of severe congenital hemophilia A or B (FVIII \<1% or FIX level ≤2%) as evidenced by a central laboratory measurement at screening or documented medical record evidence.
- For participants currently not on prophylaxis (CFC or BPA on-demand): A minimum of 4 bleeding episodes requiring BPA (inhibitor participants) or CFC (non-inhibitor participants) treatment within the last 6 months prior to screening.
- Willing and able to comply with the study requirements and to provide written informed consent and assent in the case of participants under the age of legal consent, per local and national requirements
Age in the registry: 12 years to - · Sex: Male · Does not accept healthy volunteers
Sites (54)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Hamilton | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Hamilton | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| - Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| - Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
| Vivantes Netzwerk fuer Gesundheit GmbH Coordinator of this site? Confirm its status | Berlin | Germany | Active, not recruiting |
| University Medical Center Hamburg-Eppendorf Coordinator of this site? Confirm its status | Hamburg | Germany | Active, not recruiting |
| Complexo Hospitalario Universitario A Coruña Coordinator of this site? Confirm its status | A Coruña | Spain | Active, not recruiting |
| Hospital Universitario La Paz Coordinator of this site? Confirm its status | Madrid | Spain | Active, not recruiting |
| Hospital Unviersitario Miguel Servet Coordinator of this site? Confirm its status | Zaragoza | Spain | Active, not recruiting |
| Assistance Publique Hopitaux De Paris Coordinator of this site? Confirm its status | Le Kremlin-Bicetre | France | Active, not recruiting |
| Centre Hospitalier Regional Universitaire De Lille Coordinator of this site? Confirm its status | Lille Cedex | France | Active, not recruiting |
| Assistance Publique Hopitaux de Paris Coordinator of this site? Confirm its status | Paris | France | Active, not recruiting |
| Laiko General Hospital of Athens Coordinator of this site? Confirm its status | Athens | Greece | Active, not recruiting |
| Nosokomeio Paidon I Agia Sofia Coordinator of this site? Confirm its status | Athens | Greece | Active, not recruiting |
| Ippokratio General Hospital of Thessaloniki Coordinator of this site? Confirm its status | Thessaloniki | Greece | Active, not recruiting |
| - Coordinator of this site? Confirm its status | Bangalore | India | Unknown status |
| - Coordinator of this site? Confirm its status | Bhubaneswar | India | Unknown status |
| - Coordinator of this site? Confirm its status | Pune-411011 | India | Unknown status |
| - Coordinator of this site? Confirm its status | Punjab | India | Unknown status |
| - Coordinator of this site? Confirm its status | Vellore | India | Unknown status |
| Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Coordinator of this site? Confirm its status | Milan | Italy | Active, not recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS Coordinator of this site? Confirm its status | Rome | Italy | Active, not recruiting |
| Humanitas Research Hospital Coordinator of this site? Confirm its status | Rozzano | Italy | Active, not recruiting |
| - Coordinator of this site? Confirm its status | Kashihara-shi | Japan | Unknown status |
| - Coordinator of this site? Confirm its status | Nagoya | Japan | Unknown status |
| - Coordinator of this site? Confirm its status | Saitama-shi | Japan | Unknown status |
| - Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| - Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| - Coordinator of this site? Confirm its status | Chihuahua City | Mexico | Unknown status |
| - Coordinator of this site? Confirm its status | Monterrey | Mexico | Unknown status |
| - Coordinator of this site? Confirm its status | Veracruz | Mexico | Unknown status |
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie Coordinator of this site? Confirm its status | Krakow | Poland | Active, not recruiting |
| Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi Coordinator of this site? Confirm its status | Lodz | Poland | Active, not recruiting |
| Instytut Hematologii I Transfuzjologii Coordinator of this site? Confirm its status | Warsaw | Poland | Active, not recruiting |
| Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Coordinator of this site? Confirm its status | Warsaw | Poland | Active, not recruiting |
| - Coordinator of this site? Confirm its status | Jeddah | Saudi Arabia | Unknown status |
| - Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
| - Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
| University Hospitals of Cleveland Site Number : 8400001 Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
| Children's Medical Center Dallas- Site Number : 8400018 Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| Hackensack University Site Number : 8400009 Coordinator of this site? Confirm its status | Hackensack | United States | Unknown status |
| Gulf States Hemophilia and Thrombophilia Center- Site Number : 8400002 Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| M Health Fairview University of Minnesota Medical Center - West Bank- Site Number : 8400016 Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
| Northwell Health Hemostasis and Thrombosis Center Site Number : 8400015 Coordinator of this site? Confirm its status | New Hyde Park | United States | Unknown status |
| Center for Inherited Blood Disorders (CIBD) Site Number : 8400012 Coordinator of this site? Confirm its status | Orange | United States | Unknown status |
| UPMC Children's Hospital of Pittsburgh-4401 Penn Ave Site Number : 8400017 Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Johannesburg | South Africa | Unknown status |
| - Coordinator of this site? Confirm its status | Parktown | South Africa | Unknown status |
| - Coordinator of this site? Confirm its status | Adana | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Akdeniz | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Çapa | Turkey (Türkiye) | Unknown status |
| - Coordinator of this site? Confirm its status | Izmir | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.